These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37644910)

  • 61. Empirical profile Bayesian estimation for extrapolation of historical adult data to pediatric drug development.
    Wu Y; Hui J; Deng Q
    Pharm Stat; 2020 Nov; 19(6):787-802. PubMed ID: 32573051
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Borrowing information across patient subgroups in clinical trials, with application to a paediatric trial.
    Turner RM; Turkova A; Moore CL; Bamford A; Archary M; Barlow-Mosha LN; Cotton MF; Cressey TR; Kaudha E; Lugemwa A; Lyall H; Mujuru HA; Mulenga V; Musiime V; Rojo P; Tudor-Williams G; Welch SB; Gibb DM; Ford D; White IR;
    BMC Med Res Methodol; 2022 Feb; 22(1):49. PubMed ID: 35184739
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Bayesian hierarchical models for adaptive basket trial designs.
    Chen C; Hsiao CF
    Pharm Stat; 2023; 22(3):531-546. PubMed ID: 36625301
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A BAYESIAN ADAPTIVE TWO-STAGE DESIGN FOR PEDIATRIC CLINICAL TRIALS.
    Psioda MA; Xue X
    J Biopharm Stat; 2020 Nov; 30(6):1091-1108. PubMed ID: 33019841
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Bayesian Additive Regression Trees (BART) with covariate adjusted borrowing in subgroup analyses.
    Pan J; Bunn V; Hupf B; Lin J
    J Biopharm Stat; 2022 Jul; 32(4):613-626. PubMed ID: 35737650
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Covariate handling approaches in combination with dynamic borrowing for hybrid control studies.
    Fu C; Pang H; Zhou S; Zhu J
    Pharm Stat; 2023; 22(4):619-632. PubMed ID: 36882191
    [TBL] [Abstract][Full Text] [Related]  

  • 67. On efficient posterior inference in normalized power prior Bayesian analysis.
    Han Z; Zhang Q; Wang M; Ye K; Chen MH
    Biom J; 2023 Jun; 65(5):e2200194. PubMed ID: 36960489
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Bayesian adaptive design for pediatric clinical trials incorporating a community of prior beliefs.
    Wang Y; Travis J; Gajewski B
    BMC Med Res Methodol; 2022 Apr; 22(1):118. PubMed ID: 35448963
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Improving efficiency in the stepped-wedge trial design via Bayesian modeling with an informative prior for the time effects.
    Zhan D; Ouyang Y; Xu L; Wong H
    Clin Trials; 2021 Jun; 18(3):295-302. PubMed ID: 33813906
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Propensity-score-based meta-analytic predictive prior for incorporating real-world and historical data.
    Liu M; Bunn V; Hupf B; Lin J; Lin J
    Stat Med; 2021 Sep; 40(22):4794-4808. PubMed ID: 34126656
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Enhancing generalizability and efficiency in clinical trials through dynamic information borrowing for both experimental and control arms: A simulation study.
    Yang J; Li G
    J Evid Based Med; 2023 Dec; 16(4):547-556. PubMed ID: 38148281
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Power prior for borrowing the real-world data in bioequivalence test with a parallel design.
    Huang L; Su L; Zheng Y; Chen Y; Yan F
    Int J Biostat; 2021 May; 18(1):73-82. PubMed ID: 33962492
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Dynamic borrowing from a single prior data source using the conditional power prior.
    Thompson L; Chu J; Xu J; Li X; Nair R; Tiwari R
    J Biopharm Stat; 2021 Jul; 31(4):403-424. PubMed ID: 34520325
    [TBL] [Abstract][Full Text] [Related]  

  • 74. An efficient Bayesian platform trial design for borrowing adaptively from historical control data in lymphoma.
    Normington J; Zhu J; Mattiello F; Sarkar S; Carlin B
    Contemp Clin Trials; 2020 Feb; 89():105890. PubMed ID: 31740427
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Conditional borrowing external data to establish a hybrid control arm in randomized clinical trials.
    Li H; Tiwari R; Li QH
    J Biopharm Stat; 2022 Nov; 32(6):954-968. PubMed ID: 35067183
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Optimal designs for regional bridging studies using the Bayesian power prior method.
    Nagase M; Ueda S; Higashimori M; Ichikawa K; Dunyak J; Al-Huniti N
    Pharm Stat; 2020 Jan; 19(1):22-30. PubMed ID: 31448511
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pharmacokinetic/pharmacodynamic data extrapolation models for improved pediatric efficacy and toxicity estimation, with application to secondary hyperparathyroidism.
    Basu C; Ma X; Mo M; Xia HA; Brundage R; Al-Kofahi M; Carlin BP
    Pharm Stat; 2020 Nov; 19(6):882-896. PubMed ID: 32648333
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Deep historical borrowing framework to prospectively and simultaneously synthesize control information in confirmatory clinical trials with multiple endpoints.
    Zhan T; Zhou Y; Geng Z; Gu Y; Kang J; Wang L; Huang X; Slate EH
    J Biopharm Stat; 2022 Jan; 32(1):90-106. PubMed ID: 34632951
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Bayesian sample size determination for a Phase III clinical trial with diluted treatment effect.
    Zhang YY; Ting N
    J Biopharm Stat; 2018; 28(6):1119-1142. PubMed ID: 29513608
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A decision-theoretic approach to Bayesian clinical trial design and evaluation of robustness to prior-data conflict.
    Calderazzo S; Wiesenfarth M; Kopp-Schneider A
    Biostatistics; 2022 Jan; 23(1):328-344. PubMed ID: 32735010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.